◆ NeutralERASRVMDRVMDW
Robbins LLP Urges ERAS Stockholders to Contact the Firm for Information About the Class Action Against Erasca, Inc.
GlobeNewswire Inc.·
A class action lawsuit has been filed against Erasca, Inc. (NASDAQ: ERAS) on behalf of investors who purchased securities between January 14, 2025 and April 26, 2026. Shareholders allege that Erasca failed to disclose risks related to patent and trade secret violations regarding its ERAS-0015 drug candidate. The allegations emerged after Revolution Medicines sent a cease-and-desist letter claiming patent infringement and trade secret misappropriation. Following the disclosure on April 27, 2026, Erasca's stock price fell from $21.49 to $19.15 per share.
Read Full Article at GlobeNewswire Inc. →